Blood test could slash antibiotic use in preterm infants by 30%

NCT ID NCT06100614

Recruiting now Disease control Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 09, 2026 · Updated 37 times

Summary

This study tests whether adding a blood test called presepsin to standard care can safely reduce the number of preterm babies (born before 32 weeks) who receive antibiotics unnecessarily. Currently, over 85% of these infants get antibiotics right after birth due to infection risk, but only about 1 in 70 actually has an infection. The trial will involve 900 babies across multiple hospitals, comparing those who get the presepsin-guided approach to those who follow the usual guideline. The goal is to cut unnecessary antibiotic use by at least 30% without missing any real infections.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EARLY-ONSET NEONATAL SEPSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Amsterdam UMC
RECRUITING

Amsterdam, North Holland, 1105 AZ, Netherlands

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

EARLY-ONSET NEONATAL SEPSIS